Multiple Analysts Cut Boston Scientific Price Targets, Citi Downgrades to Neutral
In September 2024, three investment firms—Bernstein, Citi, and Oppenheimer—lowered their price targets for Boston Scientific (BSX). Citi also downgraded the stock from Buy to Neutral, reducing its target from $57 to $50. Bernstein cut its target from $72 to $60, and Oppenheimer from $85 to $65. No specific reasons for the revisions were provided in the reports.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
Oppenheimer Lowers Boston Scientific Price Target to $65 From $85
On September 21, financial news outlet Cailianshe reported that Oppenheimer, an investment bank, has lowered its price target for Boston Scientific Corporation (BSX) from $85 to $65. The revision represents a significant reduction in the analyst's valuation outlook for the medical device company. The report does not specify the reasons behind the downgrade or provide any additional context regarding the company's performance or market conditions. This type of analyst action is closely watched by investors as it can influence market sentiment and trading decisions for the stock.
Citi Downgrades Boston Scientific to Neutral, Cuts Price Target to $50
On September 17, Citi downgraded its rating for Boston Scientific from Buy to Neutral and reduced its price target from $57 to $50. The downgrade reflects a shift in the bank's outlook on the medical device company's stock performance. The new price target implies a lower expected valuation compared to the previous target. The information was reported by Cailian Press, a Chinese financial news outlet.
Citi Downgrades Boston Scientific to Neutral, Lowers Price Target to $50
Citi analysts downgraded Boston Scientific (BSX.N) from Buy to Neutral and lowered the price target from $57 to $50. The downgrade reflects a revised outlook on the medical device company's stock performance. The new price target implies a lower valuation compared to the previous target. The rating change was reported by financial news source Jin10, citing Citi's assessment. No specific reasons for the downgrade were provided in the brief report. Investors may interpret this as a signal of reduced near-term upside potential for Boston Scientific shares.
Read sourceShow 2 older updatesHide older updates
Bernstein Lowers Boston Scientific Price Target to $60 From $72
According to a report from Cailian Press on September 15, investment firm Bernstein has reduced its price target for Boston Scientific, a medical device manufacturer, from $72 to $60. The revision represents a downward adjustment in the analyst's valuation outlook for the company. The report does not specify the reasons behind the target cut or provide any additional context regarding Boston Scientific's recent performance or market conditions. This forecast change is attributed solely to Bernstein and reflects the firm's updated expectations for the stock's future price.
Read sourceBernstein Lowers Boston Scientific Price Target to $60 From $72
Bernstein, a research firm, has lowered its price target for Boston Scientific Corporation (a medical device company) from $72 to $60. The revision represents a bearish adjustment in the analyst's valuation of the company's stock. The source does not provide specific reasons for the downgrade, such as changes in market conditions, company performance, or product outlook. This forecast is attributed solely to Bernstein and reflects the firm's updated opinion on the stock's potential value.